A Study in a Type of Pancreatic Cancer that has Spread Beyond the Pancreas

Registry ID

EUCTR2016-002218-36

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Eli Lilly and Company

Start date

2017-01-24

Completion date

2018-11-09

Last update

2026-08-16

Conditions

• Metastatic Pancreatic Ductal Adenocarcinoma

Summary

STAGE 1: •To evaluate disease control rate of the abemaciclib treatment arms versus the standard-of-care arm (gemcitabine or capecitabine) STAGE 2 •To evaluate progression-free survival of the abemaciclib treatment arms versus the standard of care arm (gemcitabine or capecitabine)

Locations

• , , Belgium
• , , Spain
• , , Hungary
• , , UK
• , , France

Related clinical trials

• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
• Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer

View on source registry